Rhythm Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-02-01
- Employees
- 226
- Market Cap
- -
- Website
- http://www.rhythmtx.com
- Introduction
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also...
Open-Label Extension Study of Setmelanotide
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06596135
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸UC San Diego- Rady Children's Hospital, San Diego, California, United States
🇺🇸University of Florida at Gainesville, Gainesville, Florida, United States
A Study of RM-718 in Healthy Subjects and in Patients With HO
- Conditions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06239116
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT06046443
- Locations
- 🇰🇷
Seoul National University, Seoul, Gwanak District, Korea, Republic of
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸University of Iowa Children's Hospital, Iowa City, Iowa, United States
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05774756
- Locations
- 🇬🇧
Birmingham Women and Children's Hospital NHS Trust, Birmingham, United Kingdom
🇺🇸UAN Pediatric Endocrinology, Birmingham, Alabama, United States
🇺🇸Rady Children's Hospital, San Diego, California, United States
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
- First Posted Date
- 2022-01-18
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT05194124
- Locations
- 🇵🇷
UPR Medical Sciences Campus, Rio Piedras, Puerto Rico
🇳🇱Erasmus MC, Rotterdam, Netherlands
🇩🇪Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany
An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)
- Conditions
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Registration Number
- NCT05183802
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05093634
- Locations
- 🇺🇸
UPMC Montefiore, Pittsburgh, Pennsylvania, United States
🇺🇸Marshfield Clinic Research Foundation, a Division of Marshfield Clinic, Inc, Marshfield, Wisconsin, United States
🇵🇷University of Puerto Rico, San Juan, Puerto Rico
Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT05046132
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit (Los Angeles), Glendale, California, United States
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
- Conditions
- Interventions
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04966741
- Locations
- 🇺🇸
Columbia University Medical Center, Division of Pediatric Endocrinology, Diabetes and Metabolism, New York, New York, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇬🇧Addenbrooke's Hospital, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, United Kingdom
DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 164
- Registration Number
- NCT04963231
- Locations
- 🇺🇸
Ten's Medical Center - Pediatric Endocrinology Clinic, Staten Island, New York, United States
🇺🇸The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Endocrine Associates of Dallas and Plano, Dallas, Texas, United States